ClinicalTrials.gg
Not yet recruitingNCT07835646Updated Nov 18, 2026

Evaluation of the Dietary Supplement Effect on Improvement of Hair Condition in Subjects With Occasional Hair Loss.

An interventional study of Dietary supplement for hair loss and Placebo in Occasional Hair Loss, sponsored by Lacer S.A.. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Lacer S.A. (part of Italfarmaco) · Not applicable, Interventional, and Other

Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 29 studies in Alopecia with a site in Spain — 8 open to participants now, 11 under way, 3 of them phase 3. Alopecia · Spain.

Planned enrollment
13th of 21
60 · median 100
Started
2026
with 2 others
No phase
11 of 29
3 open now
Primary completion
2027-02
later than 8 of 10 live
Registered
27th of 29
by date
Lead sponsor
2 of 29
Lacer S.A.

Among the 29 studies in Alopecia with a site in Spain, this one is the 13th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 27th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 128 are open to participants now.

Browse Alopecia studies →

Open to participants now

8 of the 29 studies in Alopecia with a site in Spain are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 76 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 48 (63%) stop at 75 or younger; 10 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Alopecia with a site in Spain, or all of them as a file.
02

Study summary

The goal of this study is to learn if dietary supplement works to help with improving hair condition in subjects with occasional hair loss. It will also learn about its safety. The main question it aims to answer is:

  • Does the dietary supplement reduce the number of hair lost by participants? Researchers will compare dietary supplement to a placebo (a look-alike substance that contains no drug) to see if it works to reduce hair loss.

Participants will:

  • Take dietary supplement or a placebo every day for 3 months
  • Visit the clinic every month for evaluations
03

Conditions studied

  • Occasional Hair Loss

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 to 70 years.
  • Self-perceived occasional telogen effluvium, with a count of 100 or more shed hairs in the standardized wash and combing test, confirmed at the screening visit (Visit 0), of recent onset (less than 6 months) and attributable to factors such as stress, nutritional deficiency, pollution, or seasonality.
  • Good general health, in the investigator's judgment, with no relevant uncontrolled systemic disease.
  • Availability and willingness to attend the three study visits and comply with study procedures over a 90-day period.
  • Agreement to receive study-related communications electronically (email and/or SMS), where expressly authorized.
  • Ability to understand the study and provide written .

Exclusion criteria

Exclusion Criteria:

  • Refusal to provide to participate in the study.

    • Inability to understand the study language.
    • Pregnancy or breastfeeding.
    • Established androgenetic alopecia (Hamilton-Norwood classification or other pattern hair loss disorders) or other forms of alopecia (alopecia areata, scarring alopecia, trichotillomania, or others) diagnosed or suspected by the investigator.
    • Use of specific pharmacological or cosmetic treatments for hair loss (minoxidil, finasteride, topical or systemic , other dietary supplements, or hair lotions) within the 3 months prior to enrollment.
    • Uncontrolled endocrine disease (e.g., thyroid disorders), diagnosed severe nutritional deficiency, untreated anemia, or a recent history (\< 6 months) of severe febrile illness, major surgery, or childbirth.
    • Active scalp dermatological conditions (psoriasis, moderate-to-severe seborrheic dermatitis, fungal or bacterial infections) that may interfere with clinical assessment or instrumental evaluation techniques.
    • Any disease, treatment, or characteristic that, in the investigator's opinion, may preclude participation due to unnecessary risk or interference with the study and/or interpretation of the results, particularly:
    • Use of aspirin or related compounds, antibiotics, anti-inflammatory drugs, corticosteroids, antidepressants, antihistamines, or treatments.
    • Ongoing allergen desensitization therapy (allergy immunotherapy).
    • Presence of dermatological abnormalities in the study area, such as irritation, erythema, scars, pigmentation disorders, numerous freckles, or nevi.
    • History of intolerance or allergy to medications or other substances that may pose an unjustified risk.
    • Use of a nutricosmetic supplement within the 3 months prior to study initiation or during the entire study period.
    • History of intolerance or allergy to cosmetic products of the same type as the product.
    • Receipt of a vaccination within the previous month or planned vaccination during the study period.
    • Surgical intervention in the study area within the month prior to study initiation or during the study.
    • Undergoing aesthetic procedures that may affect the scalp during the study, such as oxidative root hair coloring, perming, Japanese straightening, keratin straightening, or full hair bleaching (color rinses, temporary dyes, highlights, light hairstyling, and salon styling procedures are permitted).
    • Combing, washing, or dyeing the hair within the 48 hours preceding a study visit.
    • Simultaneous participation in other studies related to the same therapeutic or application area.
    • Modification of cosmetic habits in the study area within the 15 days prior to study initiation.

Exposure to intense sunlight or ultraviolet (UV) radiation within the month prior to study enrollment, or anticipated exposure during the study period.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Dietary supplement capsule

    Dietary Supplement: Dietary supplement for hair loss

  • Placebo comparator
    Placebo capsule

    Other: Placebo

Interventions

  • Dietary supplementDietary supplement for hair loss

    Dietary supplement will be taken daily for 2 months

  • OtherPlacebo

    Placebo will be taken daily for 2 months

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the number of shed hairs at 3 Months

    Hair loss will be evaluated by wash and combing test

    Time frame: From enrollment to the end of treatment at 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Only data included in the publication will be shared.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 61 industry-sponsored interventional studies with no phase under Alopecia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 3 months is below that.

Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Sep 23, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Nov 2026
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Oct 2026→Nov 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07835646
Lead sponsor
Lacer S.A.
Responsible party
Sponsor
First posted
Sep 23, 2026
Start date
Nov 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Chávez Bourgeois, Dr.
Contact
marionminisa@gmail.com
+34 937 37 64 00

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion